TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Tvardi Therapeutics ( (TVRD) ) is now available.
Tvardi Therapeutics announced significant progress in its clinical trials, particularly with its STAT3 inhibitor, TTI-101, which has shown promising results in reducing inflammation, fibrosis, and tumor growth in hepatocellular carcinoma (HCC) models. The company is also conducting ongoing Phase 1 and Phase 2 trials, with anticipated data releases in the first half of 2026, potentially impacting the treatment landscape for fibrosis-driven diseases and HCC.
The most recent analyst rating on (TVRD) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Tvardi Therapeutics stock, see the TVRD Stock Forecast page.
Spark’s Take on TVRD Stock
According to Spark, TipRanks’ AI Analyst, TVRD is a Underperform.
Cara Therapeutics receives a low overall stock score due to significant financial challenges, including declining revenues and negative profitability. Technical analysis indicates a bearish trend with weak market momentum, and valuation metrics highlight ongoing losses. These factors collectively suggest a high-risk profile for potential investors.
To see Spark’s full report on TVRD stock, click here.
More about Tvardi Therapeutics
Tvardi Therapeutics operates in the biotechnology industry, focusing on developing therapies targeting the STAT3 pathway, which is implicated in fibrosis-driven diseases and certain cancers. The company is advancing its product candidates through various stages of clinical trials, aiming to provide disease-modifying treatments.
Average Trading Volume: 283,267
Technical Sentiment Signal: Strong Sell
Current Market Cap: $37.81M
For detailed information about TVRD stock, go to TipRanks’ Stock Analysis page.